Form 4: United Therapeutics' President and COO, Michael Benkowitz, Executes Stock Options and Sells Shares Under 10b5-1 Plan

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on November 11, 2024, according to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On November 11, 2024, Michael Benkowitz, the President and COO of United Therapeutics, executed stock options and sold shares of the company's common stock.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on August 7, 2024.
• The sales were executed in multiple trades at varying prices, with weighted average prices reported for each transaction.
• The shares are held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There is no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. Rule 10b5-1 plans are frequently used to schedule these transactions in advance, reducing the risk of insider trading allegations.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to manage their stock sales in a transparent and compliant manner.
• Comparable companies such as Gilead Sciences, Amgen, and Biogen also see regular Form 4 filings related to executive stock transactions.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the relatively small volume of shares sold.

Key Dates